Now I have all the information I need. Let me write the consolidated review.

## Summary

This paper proposes a two-stage pipeline for correcting medication name errors in ASR output: Whisper-Large-v3 generates N-best hypotheses, which are then rescored by a LoRA-adapted LLM. The approach targets low-resource healthcare settings where ASR systems struggle with medication terminology.

## Strengths

- **Important problem domain**: Medication name errors in ASR can have serious patient safety consequences (e.g., "hyper-" vs "hypo-", "rifampin" vs "rifampicin," as stated in Section 1). Addressing this gap is a genuinely worthwhile research direction.
- **Reasonable architectural framework**: The two-pass ASR→LLM rescoring pipeline is well-studied in the literature (e.g., Whispering LLaMa, Hyporadise cited in Section 2), and applying it to medication names has practical merit if rigorously evaluated. The choice of LoRA for parameter-efficient adaptation is appropriate for the stated low-resource constraint (Section 3).

## Weaknesses

### Fatal

- **The paper's central claim—WER reduction—is unsupported by its own evaluation**: The abstract explicitly claims "a significant reduction in Word Error Rate (WER) across multiple epochs" (line 15), but Section 4.1 item 5 states "We used ROUGE score to evaluate the performance of the model" (line 68). WER measures edit distance between ASR output and reference (the standard ASR evaluation metric), while ROUGE measures n-gram overlap (designed for summarization). These are fundamentally different metrics, and WER is never reported anywhere in the paper. The core contribution claim is directly contradicted by the evaluation methodology actually used.

### Major

- **No interpretable baselines for comparison**: The paper provides no baseline for Whisper-Large-v3's 1-best WER (or even ROUGE) on the test set, no comparison against trivial rescoring methods (e.g., majority voting over N-best lists), and no N-best oracle. The only comparison is a vague reference to "finetuning the ASR model itself... achieving a benchmark of 21%" (Section 4.2, line 72), where the metric, dataset, and finetuning procedure are all unspecified. Without knowing the baseline performance of the unmodified ASR on the same test data, the numbers in Table 1 (7.45–25.10) cannot be interpreted as showing improvement or degradation.

- **Model inconsistency between method description and experiments**: The abstract and Figure 1 describe the system as using "LLaMA 3" (lines 15, 29), but Section 4.1 explicitly states "Llama-2-8b Instruct model" (line 64). These are different models with different capabilities. The limitations section (line 76) mentions "resource constraint thereby preventing us from being able to use the latest LLaMA model," which may explain the discrepancy but does not resolve it—the paper claims results for one model and reports experiments with another.

- **Dataset and training procedure are critically underspecified**: The dataset is described only as "about 600 medication names prescribed globally with their trade names... about 506 rows for training and the rest for testing" (line 67). This appears to be a list of drug names, yet the paper never explains: (a) what a "row" represents in the context of an ASR error correction task; (b) how N-best ASR hypotheses were generated for training (from actual audio? synthetic?); (c) what the input-output pairs for LoRA fine-tuning look like; (d) what prompt template is used (Figure 1 shows a "Prompt" box but never specifies its content); (e) whether the test set consists of audio, text, or ASR outputs. Without this information, the experimental setup cannot be understood or reproduced.

- **Results table is uninterpretable**: Table 1 contains four numbers across four epochs with no metric label (the column is simply called "Result"), no variance, no baseline row, and no indication of what the numbers represent. The values oscillate non-monotonically (13.45 → 25.10 → 7.98 → 7.45), which if this were WER would indicate the model gets dramatically worse at epoch 9 before recovering—an unexplained and concerning pattern.

### Minor

- **The abstract claims the Whisper-Large ASR model was "fine-tuned on a custom dataset, Pharma-Speak" (line 15), but the experiment section never describes any ASR fine-tuning—only LLM fine-tuning via LoRA. The relationship between this claimed ASR fine-tuning and the reported experiments is unclear.

- **The paper frames its contribution around low-resource healthcare settings (noisy environments, accented speech, multilingual conditions), but no such conditions are actually evaluated.** The evaluation appears to use only a list of drug names, without any test on accented speech, noisy audio, or multilingual inputs. While the low-resource *training* constraint is addressed (LoRA on a single V100), the low-resource *deployment* scenario motivating the work is never tested.

- **Batch size of 64 with 506 training samples yields approximately 8 gradient steps per epoch**, which is extremely coarse and makes per-epoch comparisons unreliable.

### Trivial

- None beyond what is already captured above.

## Nice-to-Haves

- Error analysis showing what types of ASR errors the LLM actually corrects (phonetically similar drug name confusions vs. memorization of a small vocabulary) would substantially strengthen the paper.
- Concrete examples of ASR hypotheses before and after LLM rescoring would demonstrate the method's practical value.
- Comparison against simple baselines (n-gram LM rescoring, majority voting from N-best list) would establish whether the LLM adds value beyond trivial approaches.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **"Not yet released" or availability concerns about LLaMA 3**: Removed per hard rules—models cited in the paper are assumed to exist.
- **Missing related works**: Removed per hard rules—cannot confirm existence of uncited works.
- **Formatting/presentation nitpicks** (e.g., figure quality, notation issues): Removed per hard rules.
- **Reproducibility concerns about undisclosed hyperparameters**: The paper actually does specify learning rate (1e-4), batch size (64), LoRA rank (4), and epochs (15); removed as nitpick.
- **Strength claim about "honest discussion of limitations"**: Filtered—the paper's limitations section acknowledges resource constraints but does not address the far more serious methodological issues (metric inconsistency, lack of baselines, underspecified dataset), so this "honesty" strength is overstated.
- **Strength claim about "Pharma-Speak dataset as a contribution"**: Filtered—a list of ~600 drug names with no specification of format, annotations, or access is not a meaningful dataset contribution.
- **Strength claim about Figure 1 making the system "reproducible in principle"**: Filtered—Figure 1 shows a high-level diagram but lacks the prompt template, input format, and training data specification needed for reproducibility.

## Novel Insights

The paper's most revealing flaw is not merely that it uses the wrong metric, but that the mismatch between WER (claimed) and ROUGE (used) highlights a deeper confusion about what the system is actually doing. If the input is truly N-best ASR hypotheses and the output is a corrected transcription, the natural metric is WER or character error rate. The use of ROUGE—a summarization metric—suggests the system may actually be performing a different task than ASR error correction (e.g., text-to-text mapping between drug names), which would explain why the paper cannot articulate what its training data looks like or how ASR hypotheses are generated.

## Suggestions

- **Replace ROUGE with WER** (or at minimum report both). The central claim is about WER reduction, so WER must be measured and reported.
- **Add a no-rescoring baseline**: Report Whisper-Large-v3's 1-best WER on the test set so readers can assess whether LLM rescoring helps at all.
- **Resolve the LLaMA 2 vs. LLaMA 3 inconsistency**: Clearly state which model was used and update the abstract/figures accordingly.
- **Specify the dataset and training procedure**: Describe what a "row" contains (ASR hypothesis + reference pair? just a drug name?), how N-best hypotheses are generated, and what the prompt template is.
- **Label the metric in Table 1** and add variance across runs, a baseline row, and an explanation for the non-monotonic behavior.

## Score and Decision

**Calibration comparison:**

| Anchor | Path | Avg Score | Comparison |
|--------|------|-----------|------------|
| High | 9WD9KwssyT.md (Zipformer ASR) | 7.50 | Strong ASR paper with extensive experiments, SOTA results, detailed ablations. This paper is far below this level. |
| High | kUuKFW7DIF.md (Multi-resolution HuBERT) | 8.00 | Well-executed speech SSL with rigorous evaluation. This paper is far below. |
| Medium | pK2636Prbq.md (CXR preference fine-tuning) | 4.25 | Medical domain, resource-constrained setting, but with real experiments and multiple evaluation protocols. This paper is below even this rejected medium-tier work. |
| Medium | PN9uaKA1Nv.md (ClinGen clinical text gen) | 5.75 | Resource-efficient clinical text generation with multiple experiments. This paper is significantly below. |
| Low | NZ5KXXDv1T.md (RL image gen, inconsistent metrics) | 2.50 | Inconsistency between claimed and used metrics, unconvincing experiments. Very similar pattern to this paper—both have a fundamental disconnect between their central claim and their actual evaluation. |
| Low | WRxCuhTMB2.md (uncertainty disentanglement) | 1.67 | Underspecified evaluation, inconsistent claims vs. evidence, poor presentation. This paper shares these issues. |
| Low | 2CxkRDMIG4.md (PR reject curves) | 1.50 | Questionable metrics, limited experiments. |

This paper sits firmly in the low anchor range. Like NZ5KXXDv1T (2.50), it has a fundamental inconsistency between its claimed metric (WER) and its actual evaluation metric (ROUGE). Like WRxCuhTMB2 (1.67), its evaluation methodology is underspecified and its results are difficult to interpret. The paper is slightly above the very bottom (1.5) because the problem domain is genuinely important and the two-pass architecture is a reasonable starting point. However, the paper is below NZ5KXXDv1T (2.50) because that paper at least had a complete experimental setup—this paper has only four uninterpretable numbers in a table, no baselines, and a dataset that is not even clearly described.

MY FINAL SCORE: <pineapple>2.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>